מדריך מפורט בקרוב
אנחנו עובדים על מדריך חינוכי מקיף עבור Magnesium Sulfate Dose (Pre-eclampsia). חזרו בקרוב להסברים שלב אחר שלב, נוסחאות, דוגמאות מהעולם האמיתי וטיפים מקצועיים.
Magnesium sulfate (MgSO4) is a naturally occurring mineral salt that serves as the drug of choice for two major obstetric emergencies: seizure prophylaxis and treatment in eclampsia/severe pre-eclampsia, and neuroprotection of the preterm fetus when delivery is anticipated before 32 weeks of gestation. In eclampsia, magnesium prevents recurrent seizures more effectively than diazepam or phenytoin, as demonstrated by the landmark Magpie trial. For neuroprotection, maternal IV magnesium sulfate reduces the risk of cerebral palsy in surviving preterm infants by approximately 30%, with the mechanism thought to involve anti-excitatory and anti-inflammatory effects on the immature brain. Magnesium sulfate acts by competitively antagonising calcium at the neuromuscular junction and within the central nervous system, reducing neuronal excitability. The therapeutic serum magnesium range for seizure prophylaxis is 2-3.5 mmol/L. The standard loading dose is 4 g IV given over 15-20 minutes (to avoid cardiovascular toxicity from rapid infusion), followed by a maintenance infusion of 1 g/hour. Treatment is continued for 24 hours after delivery or 24 hours after the last seizure, whichever is later. Magnesium toxicity is a medical emergency: monitoring for loss of the patellar (knee-jerk) reflex (occurs at 3.5-5 mmol/L, before respiratory depression) is the cornerstone of bedside safety monitoring. The antidote to magnesium toxicity is calcium gluconate 10 mL of 10% solution IV given slowly, which should be at the bedside for all women receiving magnesium infusions.
Loading dose: 4g MgSO4 IV (20mL of 20% solution) over 15-20 minutes; Maintenance: 1g/hour IV (5mL/hr of 20% solution or as per local protocol); Therapeutic range: 2-3.5 mmol/L; Toxicity: patellar reflex loss (3.5-5 mmol/L) → respiratory depression (5-6.5 mmol/L) → cardiac arrest (>6.5 mmol/L); Antidote: calcium gluconate 10mL of 10% IV over 10 minutes
- 1Confirm the indication: eclampsia (seizure in a woman with pre-eclampsia), severe pre-eclampsia (prophylaxis), or preterm delivery anticipated before 32 weeks (neuroprotection). Dose and duration differ slightly between indications.
- 2Prepare the loading dose: 4 g of MgSO4, typically as 20 mL of 20% solution (or 8 mL of 50% solution diluted to 20 mL with 0.9% NaCl). Administer IV over 15-20 minutes using an infusion pump — do not give as a bolus due to cardiac risk.
- 3Commence maintenance infusion at 1 g/hour immediately after the loading dose. This is typically delivered as 20 mL of 20% MgSO4 per hour via syringe driver, or per local pharmacy preparation.
- 4Perform baseline assessment before infusion: check and document patellar reflexes, respiratory rate, urine output, and oxygen saturation. Ensure calcium gluconate 10 mL of 10% solution is at the bedside.
- 5Monitor every 15-30 minutes: respiratory rate (must be ≥12/min), oxygen saturation, urine output (must be ≥25 mL/hour), and patellar reflexes. Loss of patellar reflex is the earliest clinical sign of toxicity and mandates stopping or reducing the infusion.
- 6If a seizure occurs in a woman already on maintenance, give a further 2-4 g IV bolus over 5-10 minutes. Nurse in left lateral position, protect airway, give oxygen, and call for senior help.
- 7Continue infusion for 24 hours after delivery in pre-eclampsia prophylaxis, or 24 hours after the last seizure in eclampsia. Discontinue gradually — abrupt cessation is acceptable as magnesium is rapidly cleared renally.
Nurse lateral, O2, protect airway; recheck BP and plan emergency delivery; call senior immediately
Eclampsia requires immediate seizure control plus antihypertensive therapy (labetalol or hydralazine if BP ≥160/110) and urgent delivery planning. MgSO4 prevents recurrent seizures more effectively than any other agent.
Start antihypertensive therapy simultaneously; plan delivery within 24-48h at this gestation
Severe pre-eclampsia with severe-range BP and neurological symptoms (headache, visual disturbance) warrants immediate MgSO4 prophylaxis to prevent eclampsia, antihypertensive therapy, and expedited delivery.
Do not delay delivery for magnesium; if delivery delayed >24h, discuss whether to continue
Fetal neuroprotection with MgSO4 reduces cerebral palsy risk by ~30% in surviving preterm infants born before 32 weeks. The drug acts on the fetal brain; maternal delivery stops the indication for continuation.
Resume at lower rate only after reflexes return; check renal function; consider serum Mg level
Absent patellar reflex indicates serum magnesium approaching the toxic range (approximately 3.5-5 mmol/L). The infusion must be stopped. Calcium gluconate is reserved for respiratory depression, not reflex loss alone — giving calcium unnecessarily risks abrupt reversal and possible seizure recurrence.
Professionals in finance and investment use Magnesium Sulfate Dose as part of their standard analytical workflow to verify calculations, reduce arithmetic errors, and produce consistent results that can be documented, audited, and shared with colleagues, clients, or regulatory bodies for compliance purposes.
University professors and instructors incorporate Magnesium Sulfate Dose into course materials, homework assignments, and exam preparation resources, allowing students to check manual calculations, build intuition about input-output relationships, and focus on conceptual understanding rather than arithmetic.
Consultants and advisors use Magnesium Sulfate Dose to quickly model different scenarios during client meetings, enabling real-time exploration of what-if questions that would otherwise require returning to the office for detailed spreadsheet-based analysis and reporting.
Individual users rely on Magnesium Sulfate Dose for personal planning decisions — comparing options, verifying quotes received from service providers, checking third-party calculations, and building confidence that the numbers behind an important decision have been computed correctly and consistently.
Extreme input values
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in magnesium sulfate dose calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Assumption violations
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in magnesium sulfate dose calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
Rounding and precision effects
In practice, this edge case requires careful consideration because standard assumptions may not hold. When encountering this scenario in magnesium sulfate dose calculations, practitioners should verify boundary conditions, check for division-by-zero risks, and consider whether the model's assumptions remain valid under these extreme conditions.
| Serum Mg Level (mmol/L) | Clinical Sign | Action |
|---|---|---|
| 2-3.5 | Therapeutic — no toxicity | Continue infusion; routine monitoring |
| 3.5-5 | Loss of patellar reflexes | STOP infusion; check urine output; do not give calcium unless RD develops |
| 5-6.5 | Respiratory depression (RR <12) | STOP infusion; calcium gluconate 1g IV over 10 minutes; O2; call senior |
| >6.5 | Cardiac arrest | Resuscitation; calcium 1-2g IV; call code blue; ICU |
| <2 | Sub-therapeutic | Increase infusion rate; check urine output |
Why is magnesium sulfate preferred over other anticonvulsants in eclampsia?
The Magpie trial (2002) showed MgSO4 reduced recurrent eclamptic seizures by 67% compared to placebo and was superior to diazepam and phenytoin in earlier trials. Additionally, MgSO4 reduces maternal mortality from eclampsia. Phenytoin and diazepam have CNS depressant side effects, neonatal respiratory depression risk, and lower efficacy for this specific indication.
What is the first sign of magnesium toxicity?
Loss of the patellar (knee-jerk) tendon reflex is the first clinical sign of magnesium toxicity, occurring at serum levels of approximately 3.5-5 mmol/L. Respiratory depression occurs at 5-6.5 mmol/L and cardiac arrest at levels above 6.5-7.5 mmol/L. The patellar reflex check is therefore the critical bedside safety monitoring tool, and the reflex must be checked and documented at least hourly.
What is the antidote for magnesium toxicity?
Calcium gluconate 10 mL of 10% solution (1 g) given slowly IV over 10 minutes is the antidote. It directly antagonises the neuromuscular effects of magnesium by competing at calcium-dependent channels. Calcium chloride can also be used but is more irritant if extravasated. Calcium gluconate should be at the bedside for every woman receiving magnesium infusion.
How does reduced urine output affect magnesium dosing?
Magnesium is almost entirely renally excreted. Oliguria (urine output <25 mL/hour) in pre-eclampsia reduces magnesium clearance and increases toxicity risk. In oliguric women, either the maintenance infusion is reduced (typically to 0.5 g/hour) or serum magnesium levels are checked frequently. The Collaborative Eclampsia Trial established that MgSO4 can still be used in renal impairment with careful monitoring.
Can magnesium cross the placenta and affect the fetus?
Yes. MgSO4 crosses the placenta freely and achieves near-equal concentrations in fetal and maternal serum. This is the mechanism of fetal neuroprotection. In the neonate, elevated magnesium may cause transient respiratory depression and reduced tone — the same toxicity syndrome as in the mother. Neonatal hypermagnesaemia is managed with calcium gluconate and respiratory support if needed.
What is the Magpie trial?
The Magpie trial (Magnesium sulPhate for Prevention of Eclampsia) was an international RCT of over 10,000 women published in The Lancet in 2002. It showed that MgSO4 halved the risk of eclampsia in women with pre-eclampsia and reduced maternal mortality. It established MgSO4 as the standard of care for severe pre-eclampsia worldwide.
For how long should MgSO4 be continued after delivery?
In the context of Magnesium Sulfate Dose, this depends on the specific inputs, assumptions, and goals of the user. The underlying formula provides a deterministic relationship between inputs and output, but real-world application requires interpreting the result within the broader context of finance and investment practice. Professionals typically cross-reference calculator output with industry benchmarks, historical data, and regulatory requirements. For the most reliable results, ensure inputs are sourced from verified data, understand which assumptions the formula makes, and consider running multiple scenarios to bracket the range of likely outcomes.
What concentration of MgSO4 solution is used?
Two concentrations are commonly available: 50% MgSO4 (5 g per 10 mL) which must be diluted before IV use, and 20% MgSO4 (2 g per 10 mL or 1 g per 5 mL) which can be used directly. A 4 g loading dose is given as 20 mL of 20% solution or 8 mL of 50% solution diluted to 20 mL. Confusion between concentrations is a major drug error risk; only one concentration should be stocked in each clinical area.
Pro Tip
Pre-make a bedside 'Magnesium Safety Card' for all obstetric units using MgSO4. It should display: (1) required monitoring frequency; (2) signs of toxicity and serum level at which each occurs; (3) action to take; (4) calcium gluconate dose and route. Laminated and kept at each monitored bedside, this simple tool prevents the most serious errors and is recommended by the Royal College of Obstetricians and Gynaecologists.
Did you know?
The use of magnesium sulfate in obstetrics predates modern evidence-based medicine. It was first used to treat eclamptic seizures in 1906 by J.O. Meigs in New Orleans, who gave it intrathecally (into the spinal fluid). In the 1920s, Lazard reported successful use of IV and IM magnesium for eclampsia in the USA. Despite this early use, MgSO4 was not widely adopted in Europe for decades — UK obstetricians favoured diazepam or phenytoin until the Collaborative Eclampsia Trial in 1995 and Magpie trial in 2002 finally established MgSO4's superiority with level-1 evidence.
References
- ›Altman D et al. (Magpie Trial). Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? Lancet 2002.
- ›Collaborative Eclampsia Trial. Which anticonvulsant for women with eclampsia? Lancet 1995.
- ›NICE Guideline NG133 — Hypertension in pregnancy. 2019 (updated 2023).
- ›Doyle LW et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Review 2009.